FDA approves blood test for colon cancer

Category: Health

The FDA has approved Guardant Health's Shield blood test as a primary screening tool for colon cancer in individuals aged 45 and older at average risk. The test shows 83% sensitivity for detecting colorectal cancer and meets Medicare coverage requirements. This approval is expected to enhance early detection and improve screening rates for colon cancer, which has a high survival rate when caught early.

Keywords: FDA approval, colon cancer, blood test

Source: WEAU

Update At: 7/30/2024

Related Sources